Article

Pharmacogenomic study of heart failure and candesartan response from the CHARM programme

2021-09-29

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Aims</h4> The Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) programme consisted of three parallel, randomised, double-blind clinical trials comparing candesartan with placebo in patients with heart failure (HF) categorised according to left ventricular ejection fraction and tolerability to an ACE inhibitor. We conducted a pharmacogenomic study of the...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 0a3eee5a-9a55-5b40-9048-66f5fcf00c13
DOI: 10.1101/2021.09.28.21263908

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenomic study of heart failure and candesartan response from the CHARM programmeDOI 10.1101/2021.09.28.21263908Read

Genetics of common forms of heart failure.Semantic proximity Read

Mapping the aetiological foundations of the heart failure spectrum using human geneticsSemantic proximity Read

Genetic architecture of heart failure with preserved versus reduced ejection fractionSemantic proximity Read

Assessing the role of rare pathogenic variants in heart failure progression by exome sequencing in 8,089 patientsSemantic proximity Read

State of play of pharmacogenetics and personalized medicine in heart failure.Semantic proximity Read

Adverse Cardiovascular Outcomes and Antihypertensive Treatment: A Genome-Wide Interaction Meta-Analysis in the International Consortium for Antihypertensive Pharmacogenomics Studies.Semantic proximity Read

The future of pharmacogenetics in the treatment of heart failure.Semantic proximity Read

Genetically proxied inhibition of angiotensinogen synthesis is associated with lower cardiovascular riskSemantic proximity Read

Heart failure pharmacogenetics: past, present, and future.Semantic proximity Read

Genetic polymorphisms associated with heart failure: A literature review.Semantic proximity Read

Effect of specific ADRB1/ADRB2/AGT genotype combinations on the association between survival and carvedilol treatment in chronic heart failure: a substudy of the ECHOS trial.Semantic proximity Read

Combining pharmacogenetics and patient characteristic polygenic scores to improve outcome prediction for Calcium Channel Blocker treatmentSemantic proximity Read